Free Trial
NYSE:SNN

Smith & Nephew (SNN) Stock Price, News & Analysis

$30.11
-0.22 (-0.73%)
(As of 10/3/2024 ET)

About Smith & Nephew Stock (NYSE:SNN)

Key Stats

Today's Range
$29.96
$30.28
50-Day Range
$28.76
$31.62
52-Week Range
$21.52
$31.72
Volume
489,286 shs
Average Volume
869,085 shs
Market Capitalization
$13.16 billion
P/E Ratio
N/A
Dividend Yield
1.79%
Price Target
N/A
Consensus Rating
Moderate Buy

Company Overview

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
37th Percentile Overall Score

SNN MarketRank™: 

Smith & Nephew scored higher than 37% of companies evaluated by MarketBeat, and ranked 745th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Smith & Nephew are expected to grow by 21.76% in the coming year, from $1.70 to $2.07 per share.

  • Price to Earnings Growth Ratio

    Smith & Nephew has a PEG Ratio of 1.36. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Smith & Nephew has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.76% of the float of Smith & Nephew has been sold short.
  • Short Interest Ratio / Days to Cover

    Smith & Nephew has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Smith & Nephew has recently increased by 1.85%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Smith & Nephew pays a meaningful dividend of 2.90%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Smith & Nephew does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Smith & Nephew will have a dividend payout ratio of 26.09% next year. This indicates that Smith & Nephew will be able to sustain or increase its dividend.

  • Read more about Smith & Nephew's dividend.
  • Percentage of Shares Shorted

    0.76% of the float of Smith & Nephew has been sold short.
  • Short Interest Ratio / Days to Cover

    Smith & Nephew has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Smith & Nephew has recently increased by 1.85%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Smith & Nephew has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Smith & Nephew this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for SNN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Smith & Nephew to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Smith & Nephew insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.00% of the stock of Smith & Nephew is held by insiders.

  • Percentage Held by Institutions

    Only 25.64% of the stock of Smith & Nephew is held by institutions.

  • Read more about Smith & Nephew's insider trading history.

SNN Stock News Headlines

Smith & Nephew plc (NYSE:SNN) Plans Dividend Increase - $0.29 Per Share
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
BlackRock International Fund Q2 2024 Commentary
See More Headlines

SNN Stock Analysis - Frequently Asked Questions

Smith & Nephew's stock was trading at $27.28 at the beginning of the year. Since then, SNN stock has increased by 10.4% and is now trading at $30.11.
View the best growth stocks for 2024 here
.

Smith & Nephew plc (NYSE:SNN) issued its quarterly earnings data on Monday, November, 17th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.59.

Top institutional investors of Smith & Nephew include Curbstone Financial Management Corp.

Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew investors own include Smith & Nephew (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ) and Pfizer (PFE).

Company Calendar

Last Earnings
11/17/2014
Today
10/03/2024
Ex-Dividend for 11/8 Dividend
10/04/2024
Dividend Payable
11/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Medical Equipment
Employees
18,452
Year Founded
1856

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.64 billion
Cash Flow
$3.11 per share
Book Value
$11.94 per share

Miscellaneous

Free Float
432,802,000
Market Cap
$13.16 billion
Optionable
Optionable
Beta
0.82

Social Links


This page (NYSE:SNN) was last updated on 10/3/2024 by MarketBeat.com Staff
From Our Partners